Holen Sie sich die Stockscreener-App
56.76
0.18%
-0.10
Handel nachbörslich:
56.90
0.14
+0.25%
Schlusskurs vom Vortag:
$56.86
Offen:
$57.15
24-Stunden-Volumen:
1.98M
Relative Volume:
1.05
Marktkapitalisierung:
$5.45B
Einnahmen:
$3.51M
Nettoeinkommen (Verlust:
$-581.60M
KGV:
-8.7129
EPS:
-6.5145
Netto-Cashflow:
$-345.93M
1W Leistung:
+9.66%
1M Leistung:
+16.43%
6M Leistung:
-20.97%
1J Leistung:
+45.73%
1-Tages-Spanne:
$55.76
$59.39
1-Wochen-Bereich:
$49.50
$59.39
52-Wochen-Spanne:
$33.03
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
56.76 | 5.46B | 3.51M | -581.60M | -345.93M | -6.5145 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Sumitomo Mitsui Trust Group Inc. Sells 205,564 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months - MarketBeat
CRISPR Therapeutics Improves Cash Position Amid Pipeline Expansion - Intellectia AI
2 Billion Reasons to Love CRISPR Therapeutics Right Now - The Motley Fool
Momentum Shift: Is CRISPR Therapeutics AG a strong growth stock2026 Update & Safe Capital Investment Plans - baoquankhu1.vn
Published on: 2026-04-13 17:48:33 - baoquankhu1.vn
Aug Highlights: What is the long term forecast for CRISPR Therapeutics AG stockMarket Sentiment Review & Entry Point Strategy Guides - baoquankhu1.vn
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know - MSN
Is CRISPR Therapeutics (CRSP) Pricing In Too Much Hope After Recent Share Price Recovery - Yahoo Finance
CRISPR’s One-Time ANGPTL3 Edit for Lipids Might Change The Case For Investing In CRISPR Therapeutics (CRSP) - Sahm
Bank Watch: What is the long term forecast for CRISPR Therapeutics AG stockWeekly Stock Report & Daily Market Momentum Tracking - baoquankhu1.vn
Is CRISPR Therapeutics AG a strong growth stock2026 Technical Patterns & Expert Approved Trade Ideas - baoquankhu1.vn
symbol__ Stock Quote Price and Forecast - CNN
CRSP Stock Price, Quote & Chart | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
Why is CRISPR Therapeutics AG stock going down2026 Technical Patterns & Daily Growth Stock Investment Tips - baoquankhu1.vn
Is CRISPR Therapeutics (CRSP) Pricing Reflect Its Sharp Five‑Year Share Price Pullback - simplywall.st
Bank of America Securities Remains a Buy on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Price-Driven Insight from (CRSP) for Rule-Based Strategy - Stock Traders Daily
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sell Signal: Should I set a stop loss on CRISPR Therapeutics AG2026 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
CRISPR Therapeutics: Potential Breakthroughs in Gene Editing - Intellectia AI
Can CRISPR Therapeutics AG stock outperform in a bear marketStock Surge & Long-Term Capital Growth Ideas - baoquankhu1.vn
Del-Sette Capital Management, LLC's CRISPR Therapeutics AG(CRSP) Holding History - GuruFocus
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - sg.finance.yahoo.com
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Genome Editing Market Is Going to Boom |• CRISPR Therapeutics • Editas Medicine - openPR.com
CRISPR Therapeutics AG (CRSP) latest stock news and headlines - Yahoo Finance Australia
Assessing CRISPR Therapeutics (CRSP) Valuation As Casgevy Revenue And Cash Position Support Its Growth Transition - Sahm
LTS:0VRQ PB Ratio: 2.47 — 22% Below Median - GuruFocus
CRISPR Therapeutics Hits Day Low of $50.66 Amid Price Pressure - Markets Mojo
Did CRISPR’s Cash Raise, Casgevy Launch and Insider Buying Just Shift CRISPR Therapeutics' (CRSP) Investment Narrative? - Sahm
CRISPR Therapeutics AG (CRSP) rises higher than market: Key facts - MSN
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):